Skip to reading
KLOWFormulation Notes

KLOW Formulation Notes / references

Here is what the KLOW peptide sources actually tested

Open a paper with one question in mind: did it test the thing the claim is about?

Which material

The full thymosin beta-4 protein and the TB-500 fragment are different materials. The study name alone may not make that obvious.

Which subjects

Lab-grown cells, injured animals and people give different kinds of answers. The study setting belongs beside the result.

Which preparation

Testing one ingredient cannot establish how a mixture holds up, what it contains or whether it helps a person.

Which question

A research finding, a regulatory document and a prescription review do different jobs. One cannot supply the answers missing from another.

The papers and documents behind these pages

These documents are linked from the articles. None reports a controlled human trial of the complete KLOW blend. Each note says what the source contributes, so an interesting ingredient finding can stay interesting without becoming a claim about the whole mixture.

GHK-Cu and collagen in lab-grown cells

Maquart and colleagues exposed cultured human skin cells to GHK-Cu in 1988 and found they made more collagen. No visible skin change in people was measured.

Getting GHK through the skin

Mortazavi and colleagues’ 2025 review examines getting GHK across the outer skin barrier and ways to improve delivery. It does not test injected KLOW.

KPV in cells and mice with bowel inflammation

Dalmasso and colleagues’ 2008 paper found reduced inflammatory activity with KPV in cells and mice with experimental bowel inflammation. It did not test KLOW in people.

Rat Achilles healing after BPC-157

Staresinic and colleagues’ 2003 experiment found better healing of surgically cut Achilles tendons in rats. It did not test human tendon complaints or the mixture.

The full thymosin beta-4 protein in rat wounds

Malinda and colleagues tested full-length thymosin beta-4 in rat wounds in 1999. The shorter TB-500 fragment cannot simply inherit those results.

FDA’s assessment of TB-500

FDA’s July 2026 assessment identifies TB-500 as a chemically capped fragment of thymosin beta-4. It explains why findings about the uncapped piece cannot transfer directly.

FDA’s assessment of BPC-157

FDA’s July 2026 assessment reviews small human studies and finds insufficient clinical safety information. Short studies with unclear safety monitoring cannot establish long-term safety.

FDA’s peptide safety concerns

FDA dates this page’s content to April 22, 2026. The four ingredients’ nominations appear as withdrawn, specifying injectable GHK-Cu; that status gives no compounding approval.

What a compounded medicine is

FDA explains why a patient might need a specially prepared medicine. Compounding does not give that medicine FDA approval. This explanation supplies no quality check for an individual preparation.

Quality problems FDA describes

FDA discusses contamination and incorrect ingredient amounts in compounded medicines. These general risks do not establish that any particular KLOW preparation has a quality problem.

How location matters in telemedicine

The medical-board federation’s 2022 model policy discusses clinical assessment and authority where the patient is located. Actual state rules and exceptions govern an appointment.

The 2026 anti-doping list

The World Anti-Doping Agency includes TB-500 among thymosin beta-4 derivatives in section S2. The prohibition applies during competition and outside it.

Wilson disease and copper handling

The National Library of Medicine describes Wilson disease as an inherited disorder involving excess copper in body tissues. This is background for a theoretical concern, not a study of GHK-Cu or KLOW in people with the condition.